TELA Bio, Inc. 8-K

What Happened

• On March 24, 2026, TELA Bio, Inc. announced its financial results for the fourth quarter of 2025 and the fiscal year ended December 31, 2025 via a press release furnished on Form 8‑K (Item 2.02). The press release is attached as Exhibit 99.1 to the filing.
• The company also updated the investor corporate slide deck used in meetings and furnished it under Regulation FD (Item 7.01). The updated presentation is attached as Exhibit 99.2. The filing also includes the Inline XBRL cover page (Exhibit 104).

Key Details

• Filing date: March 24, 2026 (Form 8‑K filed and exhibits furnished).
• Period covered: Fourth quarter 2025 and fiscal year ended December 31, 2025.
• Exhibits furnished: 99.1 (press release), 99.2 (corporate slide deck), 104 (Inline XBRL cover page).
• Disclosure type: Item 2.02 (results of operations/financial condition) and Item 7.01 (Regulation FD investor materials).

Why It Matters

• Earnings and quarterly results releases are primary sources for updates on revenue, profitability, and business trends; investors should review the furnished press release and slide deck for the specific financial metrics and management commentary.
• The updated slide deck may include refreshed guidance, strategic highlights, or operational updates that can affect investor views; because it was furnished under Regulation FD, the information is being made available publicly to ensure fair access.
• Retail investors looking for the numeric results, revenue figures, or management discussion should read the attached Exhibit 99.1 and 99.2 on the SEC EDGAR site or the company’s investor relations page.